DHEA S
- Known as:
- DHEA S
- Catalog number:
- 1
- Product Quantity:
- 5 x 96 test
- Category:
- -
- Supplier:
- Jay
- Gene target:
- DHEA
Related genes to: DHEA S
- Gene:
- SULT2A1 NIH gene
- Name:
- sulfotransferase family 2A member 1
- Previous symbol:
- STD
- Synonyms:
- DHEA-ST
- Chromosome:
- 19q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1994-03-03
- Date modifiied:
- 2016-10-05
Related products to: DHEA S
5-Androsten-3beta-OL-7, 17-Dione (DHEA) Antibody7a_Hydroxy DHEA 7a_Hydroxy DHEA7_Keto dehydroepi androsterone Keto DHEAAcP_ DHEAAnti- Dehydroepiandrosterone (DHEA) Sulfate-3 AntibodyAnti- Dehydroepiandrosterone (DHEA) Sulfate-7 AntibodyAntibody to Dehydroepiandrosterone (DHEA) Organism: Homo sapiens (Human) Type: Polyclonal Source: RabbitAntibody to Dehydroepiandrosterone (DHEA) Organism: Homo sapiens (Human) Type: Polyclonal Source: RabbitAntimicrobial Drugs: Natural Steroids: DEHYDROEPIANDROSTERONE SULPHATE (DHEA-S), Host animal: Sheep, Format: Purified monoclonal antibodyAntimicrobial Drugs: Natural Steroids: DEHYDROEPIANDROSTERONE SULPHATE (DHEA-S), Host animal: Sheep, Format: Purified monoclonal antibodyBile salt sulfotransferase,Dehydroepiandrosterone sulfotransferase,DHEA-ST,Homo sapiens,HST,HST,Human,Hydroxysteroid Sulfotransferase,ST2,ST2A1,ST2A3,STD,Sulfotransferase 2A1,SULT2A1Biotin-linked Antibody to Dehydroepiandrosterone (DHEA); Reactivity: Homo sapiens (Human) Clonality: Polyclonal Source: RabbitBovine Dehydroepiandrosterone ELISA , DHEABovine Dehydroepiandrosterone ELISA , DHEABovine Dehydroepiandrosterone(DHEA)ELISA Kit Related articles to: DHEA S
- Palbociclib has shown survival benefits in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. At present, however, no genetic predictors of palbociclib-related hematological toxicity have been validated for clinical use. The aim of this study was to evaluate whether genetic variants are associated with palbociclib toxicity and patient prognosis. Multicenter study of 113 patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer treated with palbociclib plus endocrine therapy. Genotyping of DNA from blood samples was performed to determine 18 variants in seven target genes (, , , , , , and ). Association analyses were performed to assess the relationship between the genetic variants and treatment-related toxicity and survival outcomes. Sixty-seven patients (59.3%) developed grade 3/4 neutropenia, 62 (54.9%) experienced disease progression, and 43 (38.1%) died. Although none of the univariate associations remained significant after Bonferroni correction, the multivariate analysis, adjusted for clinical variables, revealed several nominally significant associations. The gene variants rs6785049 ( = 0.01) and rs3732360 ( = 0.009) were associated with grade 3/4 neutropenia. The rs6785049 variant was associated with palbociclib treatment interruption ( = 0.03) and with worse progression-free ( = 0.003) and overall survival ( = 0.02). The findings of this exploratory study suggest potential associations between the rs6785049 variant and treatment toxicity and survival outcomes in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer treated with palbociclib. However, these hypothesis-generating findings need to be independently validated. - Source: PubMed
Publication date: 2026/09/18
Arqueros CristinaAndrés MartaServitja SòniaGiner JúliaTibau AriadnaBorrell MariaMartinez-Recio SergioBarnadas AgustíSalazar Juliana - Nonalcoholic fatty liver disease (NAFLD) frequently coexists with type 2 diabetes mellitus (T2DM), posing a significant metabolic disorder with limited dietary intervention options. Cordycepin, a food‑derived nucleoside from the edible fungus Cordyceps militaris, exhibits hypoglycemic and hypolipidemic effects, but its role in T2DM combined with NAFLD remains unknown. Here, we established a mouse model of T2DM combined with NAFLD in male KM mice using high-fructose and high‑fat diet, and streptozotocin. Both cordycepin (COR) and C. militaris water extract (CWE) attenuated glucose intolerance, dyslipidemia, hepatic steatosis, liver injury, inflammatory response and oxidative stress, with cordycepin showing superior efficacy. Multi‑omics analysis revealed that cordycepin uniquely reshaped the gut microbiota by significantly enriching the c__Clostridia, including g__Acetatifactor, g__Anaerovorax, g__Monoglobus, s__Acutalibacter_muris, and further affected liver metabolism, which was characterized by enrichment of bile acid metabolism-related pathways. Targeted bile acid metabolomics demonstrated that cordycepin specifically promoted the production of cholic acid‑7‑sulfate (CA7S), a gut‑restricted secondary bile acid, through activation of the hepatic PXR/Sult2a1 pathway. Notably, integrated correlation analysis revealed a significant positive association between CA7S and c__Clostridia (e.g., g__Monoglobus, g__Lachnoclostridium, and g__Anaerovorax), suggesting that cordycepin enhances CA7S production by enriching these Clostridia members. And CA7S activated TGR5 to stimulate glucagon‑like peptide‑1 (GLP‑1) secretion, thereby improving glucose and lipid homeostasis. Therefore, these findings demonstrate that dietary cordycepin improves T2DM combined with NAFLD by modulating gut microbiota, particularly Clostridia, and affecting the PXR/Sult2a1/CA7S/GLP‑1 pathway, thereby exerting beneficial effects on glucose and lipid homeostasis. - Source: PubMed
Publication date: 2026/09/05
Meng YingDun MengqianLiu XinyuanChen WeiboZhang ZhongmingLu ShengyuZhang GuoyingLing Jianya - The objective of this study was to assess the effects of short-chain fatty acids (SCFAs) on androstenone metabolism and associated gene expression in hepatocytes isolated from intact (boars) and castrated (barrows) male pigs. Isolated porcine hepatocytes were treated with the SCFAs acetate, propionate, and butyrate, both individually and in combination, and then incubated with androstenone. Androstenone metabolism and gene expression were subsequently assessed. Androstenone metabolism was significantly increased by propionate (P < 0.01) and all SCFA combination treatments (P < 0.0001) in hepatocytes from both boars and barrows, and by butyrate in hepatocytes from boars (P = 0.009). Several key genes were upregulated in hepatocytes from barrows; this included AKR1C1 following all SCFA combination treatments (P ≤ 0.01), UGT2A1 and SULT2A1 following treatment with the combination of propionate and butyrate (P < 0.05) and the combination of all three SCFAs (P < 0.05), and SULT1E1 following treatment with the combination of acetate and butyrate (P = 0.005). SCFA treatments did not alter gene expression in hepatocytes from boars; however, plasma levels of estrone-1-sulfate, an abundant testicular steroid in boars, were positively correlated (P < 0.05) with UGT1A1, SULT1E1, and UGT2A1 expression in response to treatment with different SCFAs. These results suggest that SCFA-induced effects on hepatic androstenone metabolism and gene expression depend on the specific SCFA profile and are influenced by testicular steroid hormones. - Source: PubMed
Lawson AustinBone ChristineParent MelissaSquires E James - Digestive system disorders (DSDs) are prevalent and burdensome conditions worldwide. The human proteome serves as a primary source for designing disease treatment targets and holds great potential for drug repurposing. We applied Mendelian randomization analyses to examine the genetic associations between 2321 plasma proteins and 47 DSDs using data from the FinnGen project, identifying 12 causal proteins and validating four (Tripartite Motif Containing 40, Sulfotransferase Family 2A Member 1, Peptidase Inhibitor 16, MHC Class I Polypeptide-Related Sequence B) of them in the UK Biobank. Mediation analysis showed that SULT2A1 may increase the risk of cholelithiasis by reducing 25-hydroxyvitamin D levels. Molecular interaction simulations indicated that the interaction between SULT2A1 and 25-hydroxyvitamin D is comparable to that with the defined substrate 24-OHChol-24-sulfate. We found that elevated levels of SULT2A1 may increase metabolism of approved drugs for cholelithiasis (i.e., ursodeoxycholic acid and chenodeoxycholic acid) by binding deoxycholic acid, thus reducing drug efficacy. We applied the AlphaFold3 strategy to simulate interactions between SULT2A1 and 10,052 small molecules, identifying 5 molecules that may competitively bind to SULT2A1, potentially enhancing the treatment efficacy of deoxycholic acid for cholelithiasis. Overall, our study reveals several causal associations between plasma proteins and DSDs and identifies SULT2A1 as a promising drug repurposing target for cholelithiasis. - Source: PubMed
Publication date: 2026/04/17
Zhang ShixuanLiu ZhenqiuSun DayanWu FeiWei YangJin LiYang ShenHuang JinshiWang Jiucun - Given the existing uncertainties regarding the link between Di(2-ethylhexyl) phthalate (DEHP) exposure and gastric cancer (GC) progression, this study aimed to clarify their association, identify the toxic targets of DEHP, and elucidate the underlying molecular mechanisms. - Source: PubMed
Publication date: 2026/07/16
Li ShenghaoPeng QingHao LiyuanMao JingyuHuo Bingjie